The Europe Opioids Market would witness market growth of 3.3% CAGR during the forecast period (2021-2027).
Chronic pain can be caused by a variety of factors. It could have started with an illness or an injury that a patient had already recovered from, yet the agony persisted. There could also be a long-term source of pain, such as arthritis or cancer. Many people experience chronic pain without ever having been injured or showing any signs of sickness.
Also, chronic pain has an impact on every aspect of the patient's life. Symptom alleviation and support are two of the most effective treatments. In order to give the necessary therapies to assist manage the pain, a multidisciplinary approach to pain management is frequently required. Outpatient pain management programs are the most common.
Depression (sometimes known as clinical depression or severe depressive disorder) is a common but significant mood illness. It creates severe symptoms that impact how individuals feel, think, and cope with daily tasks like sleeping, eating, and working. The symptoms of depression must be present for at least two weeks in order to be identified.
The United Kingdom's healthcare system, popularly known as the NHS, is a well-known and comprehensive system that is mostly sponsored by the government. It is considered to be one of the most effective and extensive healthcare systems in the world. The United Kingdom has the greatest level of spending in Europe, which is unsurprising. Furthermore, increased research efforts, increased pipeline medications, and the presence of multiple large businesses in the country present a huge opportunity for opioids in the country. The rise in the government investment in healthcare sector would also create more growth opportunities for the key market players.
German regulatory authorities' favourable payment policies in the areas of palliative care, non-abusive opioids, and opioid maintenance treatment (OMT) to treat opioid dependence (OD) have boosted potential in the opioids field.
The Germany market dominated the Europe Opioids Market by Country in 2020, and would continue to be a dominant market till 2027; thereby, achieving a market value of $356.7 million by 2027. The UK market anticipated to grow at a CAGR of 2.5% during (2021 - 2027). Additionally, The France market would showcase a CAGR of 4% during (2021 - 2027).
Based on Application, the market is segmented into Pain Management, Cough Treatment and Diarrhea Treatment. Based on Product Type, the market is segmented into Methadone, Oxycodone, Hydrocodone, Fentanyl, Codeine, Morphine and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Global Opioids Market Size will Hit $5.4 Billion by 2027, at a CAGR of 3.5%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Johnson & Johnson, AstraZeneca PLC, Boehringer Ingelheim International GmbH, Endo International PLC, Mallinckrodt PLC, Sanofi S.A., Pfizer, Inc., Teva Pharmaceuticals Industries Ltd., Sun Pharmaceutical Industries Ltd., and Purdue Pharma L.P.
By Application
By Product Type
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
